Indeed, we observed that the specific CXCR4 antagonist AMD3100 reversed PDN in two animal models of type II diabetes indicating that ongoing CXCR4/SDF-1 signaling is necessary for the manifestation of PDN. Here, CXCR4 is linked to type 2 diabetes mellitus.